Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228872 | 0.87 | KDM4E (0.61) | ALDH1A1GAAKDM4ETLR8MEN1 | |
| SCHEMBL4432713 | 0.83 | IKBKB (0.61) | ALDH1A1GAAKDM4EIKBKBTLR8 | |
| SCHEMBL29934771 | 0.83 | IKBKB (0.61) | ALDH1A1GAAKDM4EIKBKBTLR8 | |
| SCHEMBL11219489 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GAAKDM4ETLR8MEN1 | |
| SCHEMBL8130480 | 0.78 | IKBKB (0.58) | ALDH1A1GAAKDM4EIKBKBCYP3A4 | |
| SCHEMBL18641090 | 0.76 | ALDH1A1 (0.65) | ALDH1A1GAAKDM4ETLR8MEN1 | |
| SCHEMBL28320053 | 0.76 | TLR8 (0.61) | ALDH1A1GAAKDM4ETLR8KMT2A | |
| SCHEMBL11195862 | 0.75 | KDM4E (0.59) | ALDH1A1GAAKDM4ETLR8MEN1 | |
| SCHEMBL18023063 | 0.74 | ALDH1A1 (0.62) | ALDH1A1GAAKDM4ETLR8MEN1 | |
| SCHEMBL31443745 | 0.74 | IKBKB (0.67) | ALDH1A1GAAKDM4EIKBKBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270450-A1 | CHEMICAL COMPOUNDS | CSF1R, CSF3R, FLT3 | ALDH1A1 753/4885GAA 1479/4885KDM4E 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.